In:
International Journal of Cancer, Wiley, Vol. 147, No. 9 ( 2020-11), p. 2597-2610
Abstract:
What's new? CD39 is an enzyme expressed by regulatory T cells (Treg), which can suppress anti‐tumor immune responses. Recent studies have found that CD39 is also expressed by subsets of CD8+ tumor‐infiltrating lymphocytes (TILs). In the current study, the authors found that inhibiting CD39 can restore CD8+ TIL function. They also identified a SNP that may help predict dysfunctional CD39+ expression in TILs in cancer patients.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8